AVANOS MEDICAL, INC.
AVNS · Healthcare · $1.2B mkt cap · FY2025 filings · Shallow moat ·
Doesn't clear the bar
The four filters
Median gross margin 55.3% over 10y, very stable.
Median ROIC -3.0%, above the 9% hurdle in 0% of years.
Net debt/EBITDA n/ax, interest coverage -8x.
Owner earnings trend unclear, share count flat.
Margin of safety
- Owner earnings (normalized)
- —
- Est. intrinsic value / share
- —
- Recent price
- $24.97
- Discount to value
- No price data
Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).
15 years of fundamentals
The business, in plain English
AVANOS MEDICAL, INC. booked $701.2M of revenue in FY2025 in the Healthcare sector and kept 50.5% of it as gross profit — a solid-margin business by that measure. After every other cost, −10.4% of each revenue dollar reached the bottom line.
Across the filed record, revenue shrank from $1.7B (FY2012) to $701.2M (FY2025) — about −6.5% a year compounded over 13 years.
It earned −7.1% on invested capital in FY2025, with a median of −2.4% across 14 filed years. The Returns on Capital filter above scores it 0/100.
The balance sheet carried $247.7M of total debt in FY2018. Balance-Sheet Safety scores it 28/100.
The share count has held roughly flat between FY2014 and FY2025. Capital Discipline scores it 45/100.
Put together: Pricing Power is the strongest of the four filters (89/100) and Returns on Capital the weakest (0/100), which is how AVNS lands at 41/100 — a Shallow moat.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Gaps in a line mean that item isn’t in AVNS’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Moat Score history
Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.
Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars
None yet — AVNS has read Shallow moat for every logged capture since Jul 17, 2026.
Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.
Healthcare context
#221 of 440 scored Healthcare companies, ranked by Moat Score.
Nearest peers by Moat Score
- #219VIVS VIVOSIM LABS, INC.41.7 out of 100, Shallow moatShallow moat
- #220ELUT Elutia Inc.41.5 out of 100, Shallow moatShallow moat
- #222IMRX Immuneering Corporation41.3 out of 100, Shallow moatShallow moat
- #223STIM NEURONETICS, INC.41.2 out of 100, Shallow moatShallow moat
Compare AVNS with its nearest peers →All Healthcare companies on the Index →
Common questions about AVNS
- Does AVANOS MEDICAL, INC. have an economic moat?
- Based on its FY2025 SEC filings, the Moat Index scores AVANOS MEDICAL, INC. (AVNS) 41.3 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 89, returns on capital 0, balance-sheet safety 28, capital discipline 45.
- How has AVNS's Moat Score changed over time?
- The record logs 3 readings since Jul 17, 2026; the latest reads 41.3 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.